Table 3.
Individual, Country, and Follow-up Characteristics of Infants From 9 Trials Conducted in 16 Countries Beginning in 2000–2010
| Characteristic | All Countries | Low Child Mortality Settings | High Child Mortality Settings |
|---|---|---|---|
| Individuals included, No. | 5074 | 2548 | 2526 |
| Individual-level characteristics | |||
| Age at postvaccine serology sample, wk, mean (SD) | 23 (3) | 25 (4) | 21 (1) |
| Female, n (%) | 2513 (50) | 1255 (49) | 1258 (50) |
| Neither stunted nor severely stunted, n (%) | 4493 (89) | 2434 (96) | 2059 (82) |
| Individual rate of nonrotavirus gastroenteritis, episodes/100 mo, median (IQR) | 0 (0–11) | 0 (0–7) | 0 (0–12) |
| Severity of first episode of rotavirus gastroenteritis during follow-up, n (%) | |||
| Mild/moderate | 153 (65) | 57 (72) | 96 (61) |
| Severe | 84 (35) | 22 (28) | 62 (39) |
| Country-level characteristics | |||
| GDP, 2004 in USD, median (IQR) | 4745 (4721–27 405) | 27 405 (4271–34 166) | 4545 (274–4745) |
| Follow-up | |||
| Age at event, wk, median (IQR) | 41 (31–62) | 62 (35–78) | 37 (29–48) |
| Age at censoring, wk, median (IQR) | 81 (52–94) | 85 (75–96) | 54 (52–93) |
| Time from postvaccine serology sample to event/censoring, wk, median (IQR) | 53 (30–72) | 60 (47–74) | 33 (30–71) |
| Participation in follow-up 1 period, n (%) | 5074 (100) | 2548 (100) | 2526 (100) |
| Duration of participation in follow-up 1, wk, median (IQR) | 29 (25–31) | 26 (24–29) | 31 (29–31) |
| Participation in follow-up 2 period, n (%) | 3804 (80) | 2248 (88) | 1556 (61) |
| Duration of participation in follow-up 2, wk, median (IQR) | 36 (24–44) | 36 (26–45) | 37 (3–43) |
Abbreviations: GDP, gross domestic product; IQR, interquartile range.